drugset / Trial / NCT00233155

Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)

NCT00233155

Phase 2 Completed 100 enrolled NeurogesX
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of NGX-4010 administered at intervals of no less than 12 weeks over 1 year, based on the presence or return of pain, for the treatment of painful HIV-AN and PHN. Participation is limited to former study subjects from previous trials of NGX-4010 at selected sites.

Timeline

Start
2005-08
Primary completion
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Capsaicin Small molecule 8 % Topical